

Resource Summary Report

Generated by ASWG on Aug 11, 2026

Brilliant Violet 605(TM) anti-human CD4

RRID:AB_11204077

Type: Antibody

Proper Citation

BioLegend Cat# 317437, RRID:AB_11204077

Antibody Information

URL: http://antibodyregistry.org/AB_11204077

Proper Citation: BioLegend Cat# 317437, RRID:AB_11204077

Target Antigen: CD4

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: Brilliant Violet 605(TM) anti-human CD4

Description: This monoclonal targets CD4

Target Organism: cynomolgus, rhesus, human

Clone ID: Clone OKT4

Antibody ID: AB_11204077

Vendor: BioLegend

Catalog Number: 317437

Alternative Catalog Numbers: 317438

Record Creation Time: 20250820T001808+0000

Record Last Update: 20250820T075444+0000

Ratings and Alerts

No rating or validation information has been found for Brilliant Violet 605(TM) anti-human CD4.

No alerts have been found for Brilliant Violet 605(TM) anti-human CD4.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 9 mentions in open access literature.

Listed below are recent publications. The full list is available at [ASWG](#) .

Wang B, et al. (2026) Axes of biological variation in diffuse large B cell lymphoma. Cancer cell.

Sun Y, et al. (2025) TBK1 Targeting Is Identified as a Therapeutic Strategy to Enhance CAR T-Cell Efficacy Using Patient-Derived Organotypic Tumor Spheroids. Cancer immunology research, 13(2), 210.

Xie H, et al. (2025) Lymphotoxin-driven cancer cell eradication by tumoricidal CD8+ TIL. bioRxiv : the preprint server for biology.

Ma S, et al. (2024) Targeting P4HA1 promotes CD8+ T cell progenitor expansion toward immune memory and systemic anti-tumor immunity. Cancer cell.

de Cevins C, et al. (2023) Single-cell RNA-sequencing of PBMCs from SAVI patients reveals disease-associated monocytes with elevated integrated stress response. Cell reports. Medicine, 4(12), 101333.

Gao R, et al. (2021) Cancer cell immune mimicry delineates onco-immunologic modulation. iScience, 24(10), 103133.

Wang Y, et al. (2021) NAD⁺ supplement potentiates tumor-killing function by rescuing defective TUB-mediated NAMPT transcription in tumor-infiltrated T cells. Cell reports, 36(6), 109516.

Monel B, et al. (2019) HIV Controllers Exhibit Effective CD8+ T Cell Recognition of HIV-1-Infected Non-activated CD4+ T Cells. Cell reports, 27(1), 142.

Waight JD, et al. (2018) Selective FcγR Co-engagement on APCs Modulates the Activity of Therapeutic Antibodies Targeting T Cell Antigens. Cancer cell, 33(6), 1033.